HSBC Holdings’s Sage Therapeutics SAGE Stock Holding History

HSBC Holdings’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,977	Closed	-$86.7K	–	3213
2025 Q1	$86.7K	Buy	+10,977	New	+$80.4K	﹤0.01%	2838
2024 Q2	–	Sell	-83,577	Closed	-$1.57M	–	3141
2024 Q1	$1.57M	Buy	+83,577	New	+$1.93M	﹤0.01%	1595
2017 Q1	–	Sell	-6,530	Closed	-$334K	–	2513
2016 Q4	$334K	Buy	+6,530	New	+$308K	﹤0.01%	2154

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

HSBC Holdings's SAGE Position: Q2 2025 in Review

HSBC Holdings sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 10,977 shares — an estimated $86.7K sold.

HSBC Holdings first reported a position in SAGE in Q4 2016 and held it in 3 quarters. The position peaked at $1.57M in Q1 2024. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

HSBC Holdings reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
HSBC Holdings sold 10,977 Sage Therapeutics shares in Q2 2025, an estimated $86.7K.
HSBC Holdings first reported a position in Sage Therapeutics in Q4 2016 and held it in 3 quarters.
HSBC Holdings's Sage Therapeutics position peaked at $1.57M in Q1 2024.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.